A physical mechanism and global quantification of breast cancer

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Yu, Chong ^a   Wang, Jin ^a,b,c  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b JILIN UNIVERSITY   (China)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN MDM2; PROTEIN P53; E2F1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR E2F1;

ARTICLE; ATM GENE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CDK2 GENE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE REGULATORY NETWORK; GENE REPRESSION; GENETIC VARIATION; HER2 GENE; HUMAN; MDM2 GENE; ONCOGENE; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; STOCHASTIC MODEL; TUMOR SUPPRESSOR GENE; UPREGULATION; BIOLOGICAL MODEL; BREAST NEOPLASMS; EARLY CANCER DIAGNOSIS; FEMALE; GENETICS; PHENOTYPE; PRECANCEROUS CONDITIONS; PROTO ONCOGENE;

BREAST NEOPLASMS; E2F1 TRANSCRIPTION FACTOR; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, BRCA1; GENES, ERBB-2; GENES, P53; HUMANS; MODELS, GENETIC; PHENOTYPE; PRECANCEROUS CONDITIONS;

EID: 84978628257     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157422     Document Type: Article

References (44)

1. RA W. Introduction to Cancer Biology. London; 2010.
2. Jemal A. Global Cancer Statistics (vol 61, pg 69, 2011). Ca-a Cancer Journal for Clinicians. 2011; 61 (2):134-134. doi: 10.3322/caac.20115
3. Mortality Statistics. 2012;.
4. Loeb KR, Loeb LA. Significance of multiple mutations in cancer. Carcinogenesis. 2000; 21(3):379-385. doi: 10.1093/carcin/21.3.379 PMID: 10688858
5. Kandoth C, McLellan MD, Vandin F, Ye K, Niu BF, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-+. doi: 10.1038/nature12634 PMID: 24132290
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70. doi: 10.1016/S0092-8674(00)81683-9 PMID: 10647931
7. Li CH, Wang J. Quantifying the Landscape for Development and Cancer from a Core Cancer Stem Cell Circuit. Cancer Research. 2015; 75(13):2607-2618. doi: 10.1158/0008-5472.CAN-15-0079 PMID: 25972342
8. Huang S, Ernberg I, Kauffman S. Cancer attractors: A systems view of tumors from a gene network dynamics and developmental perspective. Seminars in Cell & Developmental Biology. 2009; 20 (7):869-876. doi: 10.1016/j.semcdb.2009.07.003
9. Li C, Wang J. Quantifying the underlying landscape and paths of cancer. Journal of the Royal Society, Interface / the Royal Society. 2014; 11(100). doi: 10.1098/rsif.2014.0774
10. Parikh AP, Curtis RE, Kuhn I, Becker-Weimann S, Bissell M, Xing EP, et al. Network Analysis of Breast Cancer Progression and Reversal Using a Tree-Evolving Network Algorithm. Plos Computational Biology. 2014; 10(7). doi: 10.1371/journal.pcbi.1003713 PMID: 25057922
11. Reznik E, Sander C. Extensive Decoupling of Metabolic Genes in Cancer. Plos Computational Biology. 2015; 11(5). doi: 10.1371/journal.pcbi.1004176 PMID: 25961905
12. Chen GC, Cairelli MJ, Kilicoglu H, Shin D, Rindflesch TC. Augmenting Microarray Data with Literature-Based Knowledge to Enhance Gene Regulatory Network Inference. Plos Computational Biology. 2014; 10(6). doi: 10.1371/journal.pcbi.1003666
13. Amar D, Safer H, Shamir R. Dissection of Regulatory Networks that Are Altered in Disease via Differential Co-expression. Plos Computational Biology. 2013; 9(3). doi: 10.1371/journal.pcbi.1002955 PMID: 23505361
14. Kauffman S. DIFFERENTIATION OF MALIGNANT TO BENIGN CELLS. Journal of Theoretical Biology. 1971; 31(3):429-&. doi: 10.1016/0022-5193(71)90020-8 PMID: 5556142
15. Ao P, Galas D, Hood L, Zhu X. Cancer as robust intrinsic state of endogenous molecular-cellular network shaped by evolution. Medical Hypotheses. 2008; 70(3):678-684. doi: 10.1016/j.mehy.2007.03. 043 PMID: 17766049
16. Flobak A, Baudot A, Remy E, Thommesen L, Thieffry D, Kuiper M, et al. Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling. Plos Computational Biology. 2015; 11(8). doi: 10. 1371/journal.pcbi.1004426 PMID: 26317215
17. Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, et al. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. Bmc Medical Genomics. 2010; 3. doi: 10.1186/1755-8794-3-26 PMID: 20591134
18. Scata KA, El-Deiry WS. P53, BRCA1 and breast cancer chemoresistance. Breast Cancer Chemosensitivity. 2007; 608:70-86.
19. Lin WY, Brock IW, Connley D, Cramp H, Tucker R, Slate J, et al. Associations of ATR and CHEK1 Single Nucleotide Polymorphisms with Breast Cancer. Plos One. 2013; 8(7):8. doi: 10.1371/journal.pone. 0068578
20. Garner E, Martinon F, Tschopp J, Beard P, Raj K. Cells with defective p53-p21-pRb pathway are susceptible to apoptosis induced by p84N5 via caspase-6. Cancer Research. 2007; 67(16):7631-7637. doi: 10.1158/0008-5472.CAN-07-0334 PMID: 17699767
21. Deisenroth C, Zhang Y. The Ribosomal Protein-Mdm2-p53 Pathway and Energy Metabolism: Bridging the Gap between Feast and Famine. Genes & cancer. 2011; 2(4):392-403. doi: 10.1177/ 1947601911409737
22. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(26):14973-14977. doi: 10.1073/pnas.96. 26.14973 PMID: 10611322
23. Das KC, Dashnamoorthy R. Hyperoxia activates the ATR-Chk1 pathway and phosphorylates p53 at multiple sites. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2004; 286(1): L87-L97. doi: 10.1152/ajplung.00203.2002 PMID: 12959929
24. Smith J, Tho LM, Xu NH, Gillespie DA. In: Woude GFV, Klein G, editors. The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer. vol. 108 of Advances in Cancer Research. San Diego: Elsevier Academic Press Inc; 2010. p. 73-112.
25. Chou WW, Guh JY, Tsai JF, Hwang CC, Chiou SJ, Chuang LY. Arecoline-induced Phosphorylated p53 and p21(WAF1) Protein Expression is Dependent on ATM/ATR and Phosphatidylinositol-3-Kinase in Clone-9 Cells. Journal of Cellular Biochemistry. 2009; 107(3):408-417. doi: 10.1002/jcb.22137 PMID: 19343784
26. Nevins JR. The Rb/E2F pathway and cancer. Human Molecular Genetics. 2001; 10(7):699-703. doi: 10.1093/hmg/10.7.699 PMID: 11257102
27. Papanikolaou V, Iliopoulos D, Dimou I, Dubos S, Tsougos I, Theodorou K, et al. The involvement of HER2 and p53 status in the regulation of telomerase in irradiated breast cancer cells. International Journal of Oncology. 2009; 35(5):1141-1149. PMID: 19787269
28. Xia WY, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, et al. Phosphorylation/cytoplasmic localization of p2l(Cip1)/(WAF1) is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clinical Cancer Research. 2004; 10(11):3815-3824. doi: 10.1158/1078-0432.CCR-03-0527 PMID: 15173090
29. Li CH, Wang J. Quantifying Cell Fate Decisions for Differentiation and Reprogramming of a Human Stem Cell Network: Landscape and Biological Paths. Plos Computational Biology. 2013; 9(8):14. doi: 10.1371/journal.pcbi.1003165
30. Wang J, Li CH, Wang EK. Potential and flux landscapes quantify the stability and robustness of budding yeast cell cycle network. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(18):8195-8200. doi: 10.1073/pnas.0910331107 PMID: 20393126
31. Wang J, Zhang K, Xu L, Wang E. Quantifying the Waddington landscape and biological paths for development and differentiation. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(20):8257-8262. doi: 10.1073/pnas.1017017108 PMID: 21536909
32. Storey KB, Storey JM. Metabolic rate depression in animals: transcriptional and translational controls. Biological Reviews. 2004; 79(1):207-233. doi: 10.1017/S1464793103006195 PMID: 15005178
33. Dang CV. Links between metabolism and cancer. Genes & Development. 2012; 26(9):877-890. doi: 10.1101/gad.189365.112
34. Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. Journal of Clinical Investigation. 2000; 105(4):533-539. doi: 10.1172/JCI8625 PMID: 10683383
35. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012; 33(11):2007-2017. doi: 10.1093/carcin/bgs232 PMID: 22822097
36. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Research. 2001; 61(12):4744-4749. PMID: 11406546
37. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004; 5(4):317-328. doi: 10.1016/ S1535-6108(04)00083-2 PMID: 15093539
38. Burga LN, Hu H, Juvekar A, Tung NM, Troyan SL, Hofstatter EW, et al. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Research. 2011; 13(2):18. doi: 10.1186/bcr2850
39. Al-Mulla F, Abdulrahman M, Varadharaj G, Akhter N, Anim JT. BRCA1 gene expression in breast cancer: A correlative study between real-time RT-PCR and immunohistochemistry. Journal of Histochemistry & Cytochemistry. 2005; 53(5):621-629. doi: 10.1369/jhc.4A6544.2005
40. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Human Molecular Genetics. 2001; 10(7):705-713. doi: 10.1093/hmg/10.7.705 PMID: 11257103
41. Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation (vol 13, R3, 2011). Breast Cancer Research. 2012; 14(2):2. doi: 10.1186/bcr3130
42. Wang H, Nan L, Yu D, Agrawal S, Zhang RW. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: In vitro and in vivo activities and mechanisms. Clinical Cancer Research. 2001; 7(11):3613-3624. PMID: 11705884
43. Wang J, Xu L, Wang EK. Potential landscape and flux framework of nonequilibrium networks: Robustness, dissipation, and coherence of biochemical oscillations. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(34):12271-12276. doi: 10.1073/pnas. 0800579105 PMID: 18719111
44. Sasai M, Wolynes PG. Stochastic gene expression as a many-body problem. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(5):2374-2379. doi: 10.1073/ pnas.2627987100 PMID: 12606710